Prevalence and Determinants of Depression, Anxiety, and Quality of Life in Patients With Breast Cancer in Saudi Arabia: A Focus on Adjuvant Pharmacotherapy Authors: Mahmoud S Abdallah, Ahmed R Gardouh, Zafaran Khalid Abuaeaaq, Amal Mohammad Badawoud Published: 2026 ABSTRACT ABSTRACTBackground and AimWhile psychological distress is a well‐documented concern among cancer patients, the prevalence and severity of depression and anxiety in breast cancer patients in Saudi Arabia remain insufficiently explored. This study aimed to evaluate depression, anxiety, and quality of life (QoL) among patients with breast cancer undergoing adjuvant pharmacotherapy in Saudi Arabia.MethodsA cross‐sectional observational study was conducted among patients with breast cancer receiving adjuvant therapy. Data were collected using the Patient Health Questionnaire‐9 (PHQ‐9) for depression, the Generalized Anxiety Disorder‐7 (GAD‐7) for anxiety, and the Quality‐of‐Life Questionnaire‐C30 (QLQ‐C30) for QoL assessment.ResultsAmong 246 patients, the most prevalent cancer subtype was hormone receptor–positive (65.0%), followed by human epidermal growth factor receptor 2 (HER2)‐positive (13.4%), triple‐negative (11.0%), and HER2/hormone receptor‐positive (10.6%). Trastuzumab (20.3%) and pembrolizumab (11.0%) were the most commonly administered biological therapies, while letrozole (45.5%) and tamoxifen (22.8%) were the most used hormonal agents. Notably, 48.4% of patients received chemotherapy. The mean ± standard deviation (SD) of PHQ‐9 score was 12.87 ± 7.63, and the mean ± SD of GAD‐7 score was 9.55 ± 5.53, with clinical significant depression and anxiety of 54.1% and 49.6%, respectively. The mean ± SD of the QLQ‐C30 score was 58.84 ± 24.98. Multivariate analysis revealed that chemotherapy and the number of cycles were significantly associated with higher levels of depression and anxiety. Quality of life was negatively impacted by chemotherapy, endocrine therapy, and the number of treatment cycles.ConclusionDepression, anxiety, and reduced QoL are prevalent among breast cancer patients undergoing treatment in Saudi Arabia. Chemotherapy and endocrine therapy contribute significantly to psychological distress, and diminished QoL.Keywords: anxiety, breast cancer, depression, pharmacotherapy, quality of life, Saudi Arabia Introduction Breast cancer is the most prevalent cancer among women worldwide, with an estimated 1 in 8 women anticipated to receive a diagnosis during their lifetime [1]. The National Comprehensive Cancer Network (NCCN) characterizes distress among cancer patients as a multifaceted, adverse emotional experience encompassing psychological (cognitive, behavioral, emotional), social, and/or spiritual dimensions that may hinder effective coping with cancer, its physical manifestations, and its treatment [2]. Psychological discomfort, a distinct type of stress, includes a wide array of feelings and mental symptoms, such as sadness and anxiety [2]. The prevalence of depression among cancer patients is uncertain, with past studies reporting rates up to 58%. This variation can be attributed to several factors, such as the diverse tools used to assess depression, each with varying psychometric properties; differences in the criteria used to define depression; and the variability in the cancer populations studied, including differences in cancer types, stages, and treatment methods [3]. Anxiety is also a prevalent psychological symptom among patients with breast cancer, with rates up to 41.9% [30.7–53.2] [4]. Recent reports indicate that depression affects up to 20% and anxiety 10% of cancer patients, compared to the prevalence in the general population, which is 5% for depression and 7% for anxiety [5]. Anxiety is a complex construct that involves cognitive, physiological, and physical domains [6]. In patients with breast cancer, it can lead to fatigue, poor treatment outcomes, and decreased quality of life (QoL) while also impacting the neuroendocrine and immune systems. The anticipation of negative outcomes, uncertainty about the future, worries about disease recurrence, and fears of treatment side effects contribute to heightened anxiety levels in these individuals [7]. It was reported that chemotherapy increased depression among cancer patients, with the prevalence of moderately severe depression and anxiety nearly doubling during treatment compared to pre‐chemotherapy levels [8]. Chemotherapy administration correlates with psychological distress, particularly with an increased number of cycles received [9]. Conversely, trastuzumab did not significantly affect fatigue or return to work in localized breast cancer. However, it was associated with increased feelings of helplessness, likely due to the intensified follow‐up requirements [10]. In another study, trastuzumab did not negatively impact fatigue or QoL compared to chemotherapy alone. After 9 months of treatment, fatigue improved similarly in women regardless of trastuzumab use [11]. Both depression and anxiety have poor prognostic implications for breast cancer. A systematic literature review and meta‐analysis included 17 eligible studies involving 282,203 patients with breast cancer. The findings indicated that depression was linked to cancer recurrence, all‐cause mortality, and cancer‐specific mortality. In contrast, anxiety was associated with recurrence and all‐cause mortality but not with cancer‐specific mortality. Furthermore, the comorbidity of depression and anxiety was related to both all‐cause mortality and cancer‐specific mortality [12]. A similar meta‐analysis included 51 suitable cohort studies with 2,611,907 participants, with a mean follow‐up duration of 10.3 years. The findings indicated that both depression and anxiety were strongly correlated with an elevated risk of cancer incidence, cancer‐specific mortality, and overall mortality in cancer patients. The anticipated absolute risk increases (ARIs) associated with depression and anxiety were 34.3 events per 100,000 person‐years for cancer incidence and 28.2 events per 100,000 person‐years for cancer‐specific death [7]. Although the psychological impact of diagnosis and treatment is well established, there is limited knowledge regarding the prevalence and risk factors of clinically significant depression and anxiety in women diagnosed with breast cancer. Additionally, addressing and diagnosing anxiety and depression in these patients can improve outcomes, enhance adherence to adjuvant pharmacotherapy, and increase survival rates [13]. The psychological consequences of breast cancer diagnosis and treatment are extensively documented; nevertheless, the particular prevalence and risk factors for clinically profound anxiety and depression among patients with breast cancer in Saudi Arabia remain less understood. This study aims to fill these gaps and underscore the significance of recognizing and addressing these mental health disorders and the related QoL to improve psychological well‐being and cancer treatment results. Methods Study Design This observational, cross‐sectional, multicenter study was conducted among patients with breast cancer undergoing adjuvant pharmacotherapy in Saudi Arabia. Data collection began in November 2024 and continued until the required sample size was reached in March 2025. Ethics Statement Ethical approval was obtained from the Institutional Review Board (IRB) of the Faculty of Pharmacy, Jadara University, with IRB number (PHARM‐JA‐12/2024); the research center and studies department in AL‐Jouf health research cluster, Ministry of Health, Sakakah, Kingdom of Saudi Arabia (2–2025); and the Tabuk Institutional review board (TU‐077/025/330). Written informed consent was obtained from all participants prior to recruitment. All data were anonymized to ensure confidentiality. The study was conducted in accordance with relevant ethical standards and guidelines, including the Declaration of Helsinki and its subsequent amendments or comparable ethical standards. Inclusion and Exclusion Criteria The study included women aged 18 years or older diagnosed with breast cancer who were undergoing adjuvant pharmacotherapy, able to provide informed consent, and willing to participate in psychological and QoL assessments. The exclusion criteria included patients with known psychiatric disorders unrelated to breast cancer and those unable to complete the questionnaires due to cognitive or communication impairments. Sample Size Calculation Based on previous studies, a minimum sample size of 246 patients was required to estimate the prevalence of depression and anxiety with a 95% confidence level and a 6% margin of error. The calculation assumed a depression prevalence of 36% and an anxiety prevalence of 24% [14]. The following formula was applied [15]: where n = required sample size, Z = 1.96 for a 95% confidence interval, P = expected prevalence (0.36), and d = margin of error (0.06). Chemotherapy Protocols Patients in this study received various standard adjuvant chemotherapy regimens used at the hospital. These included the following protocols: AC: doxorubicin + cyclophosphamide, 21‐day cycles for 4 cycles. AC: doxorubicin + cyclophosphamide, 21‐day cycles for 4 cycles. AC‐T: doxorubicin + cyclophosphamide + taxane, 14‐day cycles followed by paclitaxel. AC‐T: doxorubicin + cyclophosphamide + taxane, 14‐day cycles followed by paclitaxel. AC‐TH: doxorubicin + cyclophosphamide + taxane + trastuzumab, 21‐day cycles followed by weekly paclitaxel for 12 weeks and trastuzumab weekly for 52 weeks. AC‐TH: doxorubicin + cyclophosphamide + taxane + trastuzumab, 21‐day cycles followed by weekly paclitaxel for 12 weeks and trastuzumab weekly for 52 weeks. FEC: 5FU + epirubicin + cyclophosphamide, 21‐day cycles for 6–8 cycles. FEC: 5FU + epirubicin + cyclophosphamide, 21‐day cycles for 6–8 cycles. FEC‐T: 5FU + epirubicin + cyclophosphamide + taxane, 6 cycles (3 initial cycles followed by 3 cycles of docetaxel). FEC‐T: 5FU + epirubicin + cyclophosphamide + taxane, 6 cycles (3 initial cycles followed by 3 cycles of docetaxel). FEC‐TH: 5FU + epirubicin + cyclophosphamide + taxane + trastuzumab, 6 cycles (3 initial cycles followed by 3 cycles of docetaxel + trastuzumab). FEC‐TH: 5FU + epirubicin + cyclophosphamide + taxane + trastuzumab, 6 cycles (3 initial cycles followed by 3 cycles of docetaxel + trastuzumab). TC: docetaxel + cyclophosphamide, 21‐day cycles for 4 cycles. TC: docetaxel + cyclophosphamide, 21‐day cycles for 4 cycles. TCH: docetaxel + carboplatin + trastuzumab, 21‐day cycles for 6 cycles with trastuzumab from cycle 2 for 1 year. TCH: docetaxel + carboplatin + trastuzumab, 21‐day cycles for 6 cycles with trastuzumab from cycle 2 for 1 year. CMF: cyclophosphamide + methotrexate + 5FU, 28‐day cycles for 6 cycles, administered on days 1 and 8. CMF: cyclophosphamide + methotrexate + 5FU, 28‐day cycles for 6 cycles, administered on days 1 and 8. Data Collection Tools The study utilized a data collection form alongside three self‐administered questionnaires using a single, cross‐sectional evaluation conducted while participants were undergoing adjuvant pharmacotherapy, without reference to a standardized timepoint relative to treatment cycles. Depression and anxiety were assessed using the Patient Health Questionnaire‐9 (PHQ‐9) and the Generalized Anxiety Disorder‐7 (GAD‐7), respectively, both of which are brief instruments with established validity and high internal consistency. The Arabic versions of these tools have previously been validated for use within Saudi and regional populations [16, 17, 18], supporting their cultural fitting for the present study. The tool is publicly available for clinical and research use without licensing fees via the PHQ Screeners website. It was used without modification and scored according to standard guidelines. Quality of life was evaluated using the quality of life questionnaire‐C30 (QLQ‐C30), a widely recognized instrument for use with cancer patients that assesses physical, emotional, and social functioning. The Arabic version of this instrument has likewise demonstrated acceptable reliability in prior research and has been employed in earlier studies conducted within the region [19, 20]. These instruments were selected on the basis of their sound psychometric properties, their suitability for the target population, and their capacity to facilitate comparison with findings from previous local and international research. Data collection form: Used to record sociodemographics, cancer characteristics, comorbidities, prior surgery, and details of adjuvant pharmacotherapy. Data collection form: Used to record sociodemographics, cancer characteristics, comorbidities, prior surgery, and details of adjuvant pharmacotherapy. PHQ‐9 (Patient Health Questionnaire‐9): Assessed the severity of depression through nine items rated on a 4‐point Likert scale (0 to 3), with total scores ranging from 0 to 27. PHQ‐9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively. The cutoff point for clinically significant depression for PHQ‐9 score was ≥ 10 [21]. PHQ‐9 (Patient Health Questionnaire‐9): Assessed the severity of depression through nine items rated on a 4‐point Likert scale (0 to 3), with total scores ranging from 0 to 27. PHQ‐9 scores of 5, 10, 15, and 20 represented mild, moderate, moderately severe, and severe depression, respectively. The cutoff point for clinically significant depression for PHQ‐9 score was ≥ 10 [21]. GAD‐7 (Generalized Anxiety Disorder‐7): Measured anxiety levels via seven items rated from 0 (not at all) to 3 (nearly every day), with scores ranging from 0 to 21. GAD‐7 scores of 5, 10, and 15 represented mild, moderate, and severe anxiety, respectively [17]. The cutoff point for clinically significant anxiety for GAD‐7 score was ≥ 10 [18]. GAD‐7 (Generalized Anxiety Disorder‐7): Measured anxiety levels via seven items rated from 0 (not at all) to 3 (nearly every day), with scores ranging from 0 to 21. GAD‐7 scores of 5, 10, and 15 represented mild, moderate, and severe anxiety, respectively [17]. The cutoff point for clinically significant anxiety for GAD‐7 score was ≥ 10 [18]. QLQ‐C30 (Quality of Life Questionnaire‐C30): Evaluated QoL using 30 items covering physical, emotional, cognitive, and social functioning, and cancer‐related symptoms [22, 23, 24]. The QLQ‐C30 is composed of three main domains (functioning domain, symptoms domain, and global domain). The total and subscale scores are expressed as normalized values. The symptoms and functioning scores were reversed to follow the global scales' interpretation, that is, 0 represents the worst possible score and 100, the best possible score. The European Organization for Research and Treatment of Cancer (EORTC) permitted the use of the questionnaire for research purposes through an official e‐mail. QLQ‐C30 (Quality of Life Questionnaire‐C30): Evaluated QoL using 30 items covering physical, emotional, cognitive, and social functioning, and cancer‐related symptoms [22, 23, 24]. The QLQ‐C30 is composed of three main domains (functioning domain, symptoms domain, and global domain). The total and subscale scores are expressed as normalized values. The symptoms and functioning scores were reversed to follow the global scales' interpretation, that is, 0 represents the worst possible score and 100, the best possible score. The European Organization for Research and Treatment of Cancer (EORTC) permitted the use of the questionnaire for research purposes through an official e‐mail. Data Collection Participants completed the PHQ‐9, GAD‐7, and QLQ‐C30 questionnaires during routine follow‐up visits at different daytimes, depending on their preference and clinical feasibility. The pharmacist also used the data collection form during these interactions. Recruitment Patients were recruited from oncology clinics and hospitals in Saudi Arabia (Qurayyat General Hospital, King Abdulaziz Specialist Hospital, and King Fahad Specialist Hospital Tabuk). Recruitment was carried out through direct invitations during follow‐up visits. Statistical Analysis Descriptive statistics, including frequencies, percentages, means, standard deviations (SD), medians, and interquartile ranges (IQR) were used to summarize patient demographics, disease characteristics, and psychological scores. Inferential statistics using t‐tests and analysis of variance (ANOVA) followed by post hoc analyses (e.g., Tukey's HSD) for the reported scores. The normality of psychological scores was checked using the Kolmogorov–Smirnov test, although our sample size aligns with the sample size required for the central limit theorem [25]. Statistical tests of significance were used to examine associations between depression, anxiety, QoL, and sociodemographic and clinical factors. Pearson correlation was used to detect the relationship between variables. Multivariate analysis using linear regression identified predictors of depression, anxiety, and QoL, including demographic variables, cancer stage, and the type of adjuvant pharmacotherapy. A p‐value of ≤ 0.05 was considered statistically significant. All statistical analyses were performed using SPSS version 27. Results Sociodemographic and Clinical Data A detailed breakdown of the sociodemographic and clinical characteristics of the 246 patients with breast cancer, along with data on the adjuvant pharmacotherapy received, is presented in Table 1. TABLE 1Data of patients with breast cancer.Number (n = 246)%Age, mean (SD)53.538.59ResidenceRural6827.6Urban17872.4Social statusSingle3112.6Married10643.1Divorced5422.0Widowed5522.4Number of childrenNone4618.71–210743.5More than 29337.8Education levelSchool4819.5Bachelor or equivalent13755.7Post graduate6124.8ReligionMuslim246100Monthly salaryNot sufficient00Sufficient15362.2More than sufficient9337.8Surgery historyLobectomy17470.7Mastectomy7229.3Diabetes mellitus9137.0Hypertension4919.9Postmenopausal12550.8TypesHER2‐positive3313.4HER2‐positive, HR positive2610.6HR positive16065Triple negative2711.0TNM anatomical stage09739.4IA9739.4IB20.8IIA114.5IIB62.4IIIA218.5IIIB93.7IIIC31.2Lymph nodes involved5020.3Metastatic00.0Disease duration (months) Median (IQR)93–18Biological therapyTrastuzumab5020.3Pembrolizumab2711.0Endocrine therapyLetrozole11245.5Goserelin187.3Tamoxifen5622.8Chemotherapy protocolNone12751.6AC31.2AC‐T3012.2AC‐TH197.7CMF72.8FEC114.5FEC‐T145.7FEC‐TH83.3TC41.6TCH239.3At which cycle1197.72228.932911.842610.65104.16135.3Cycles, median (IQR)32–4 Note: A sufficient salary provides financial stability without hardship.Abbreviations: HER2, human epidermal growth factor receptor 2; HR, hormone receptors; IQR, interquartile range; SD, standard deviation; TNM, Tumor, Node, Metastasis (TNM) staging system. Data of patients with breast cancer. Note: A sufficient salary provides financial stability without hardship. Abbreviations: HER2, human epidermal growth factor receptor 2; HR, hormone receptors; IQR, interquartile range; SD, standard deviation; TNM, Tumor, Node, Metastasis (TNM) staging system. Depression Assessment The depression assessment using the PHQ‐9 scale among the patients with breast cancer revealed that a loss of interest or pleasure in activities was reported by 42.7% (n = 105) of patients as occurring more than half the days or nearly every day. Similarly, feeling down, depressed, or hopeless was frequently reported, with 47.2% (n = 116) experiencing these emotions more than half the days or nearly every day. Fatigue and low energy were also prevalent, with 42.3% (n = 104) experiencing these symptoms frequently. Sleep disturbances affected a large portion of patients, with 42.3% (n = 104) reporting trouble falling or staying asleep or sleeping too much on more than half the days or nearly every day. Notably, thoughts of self‐harm or suicidal ideation were reported by 45.5% (n = 112) at least several days a week, highlighting a critical concern for mental health support in this population. The mean PHQ‐9 score was 12.87, with an SD of 7.63, indicating that a significant proportion of patients experienced moderate to severe depressive symptoms. More than half of the respondents (54.07%) exhibited clinically significant levels of depression (PHQ‐9 score ≥ 10), with severe depression noted in over a quarter of the sample (27.24%). Anxiety Assessment The anxiety assessment using the GAD‐7 scale among the patients with breast cancer revealed that feeling nervous, anxious, or on edge was commonly reported, with 42.3% (n = 104) experiencing it over half the days or nearly every day. Similarly, excessive worrying was prevalent, with 41.5% (n = 102) struggling to control their worries frequently. Trouble relaxing was reported by 44.3% (n = 109) of patients on more than half the days or nearly every day, and restlessness was also a frequent issue, affecting 41.9% (n = 103). Irritability was another notable symptom, with 40.2% (n = 99) feeling easily annoyed or irritable over half the days or nearly every day. Additionally, feeling afraid as if something awful might happen was reported frequently by 45.5% (n = 112). The mean GAD‐7 score was 9.55, with an SD of 5.53, indicating that many patients experienced mild to moderate anxiety, with a subset showing more severe symptoms. Nearly half of the sample (49.59%) met the criteria for clinically significant anxiety (GAD‐7 score ≥ 10), with 28.5% reporting severe anxiety. Quality of Life Assessment Significant physical, functional, and emotional burdens among patients with breast cancer were reported. Regarding strenuous activities, 57 patients reported no trouble, while 85 and 50 experienced a little and quite difficulties, and 54 had severe limitations. Mobility impairments were evident, with 70 patients reporting no difficulty in taking long walks, while 86 had mild, 42 had moderate, and 48 had severe limitations. Similarly, short‐walk limitations were notable (64 reported no trouble, 99 had mild, 39 had moderate, and 44 had severe). Fatigue and rest needs were prevalent, with 64 patients reporting no need to rest, while 98 had mild and 41 had moderate limitations. Pain affected 69 patients minimally, but 96 had mild, 35 had moderate, and 46 had severe pain. Sleep disturbances were common, affecting 109 patients mildly and 47 moderately. Psychological symptoms, such as worry (74 reported no trouble, 91 had mild, 46 had moderate, and 35 had severe) and depression (75 reported no trouble, 98 had mild, 33 had moderate, and 40 had severe), were also notable. Treatment‐related social and financial impacts were significant, with 71 reporting no interference in family life but 97 experiencing mild effects. Financial difficulties were not found to be substantial in the majority of patients (142), while 78 had quite a bit, and only 26 had difficulties. In details, 142 patients (57.7%) reported no or only a little financial difficulty, while 78 (31.7%) reported quite a bit and 26 (10.6%) reported very much. The mean ± SD for overall health and QoL was 58.84 ± 24.98, suggesting a moderate perception of well‐being. Depression‐Associated Factors Social status significantly influenced depression scores (p = 0.004), with widowed patients exhibiting significantly lower depression scores compared to single, married, and divorced patients, according to the post hoc analysis. No significant difference in depression was found between rural and urban residents (p = 0.120). Both age and disease duration showed significant negative correlations with depression scores (p < 0.001), indicating that older patients and those with longer disease durations experienced lower levels of depression. Diabetes mellitus (DM) and hypertension (HTN) did not show significant associations with the PHQ‐9 scores. Treatment modalities were strongly associated with depression levels: patients who underwent chemotherapy or biological therapy had significantly higher depression scores compared to those who did not receive these treatments (all p‐values < 0.001). Notably, patients receiving endocrine therapy demonstrated lower depression scores as compared to patients assigned to chemotherapy (p < 0.001), as shown in Table 2. TABLE 2Depression associated factors among patients with breast cancer.PHQ‐9MeanSDTest‐statistic p Social€Singleb 13.618.3094.470.004* Marriedb 13.377.574Divorcedb 14.637.725Widoweda 9.756.450Residence¥Rural11.657.525−1.550.120Urban13.337.635Diabetes mellitus¥Yes13.247.52−0.5950.552No12.657.71Hypertension¥Yes13.087.630.870.387No12.027.64Age§−0.286< 0.001* Disease duration§−0.393< 0.001* Chemotherapy¥Yes19.983.735−32.9< 0.001* No6.22.714Endocrine therapy¥Yes10.747.37112.24< 0.001* No19.453.586Biological therapy¥Yes19.883.804−15.11< 0.001* No9.676.74 Note: ¥, t‐test; €, one‐way ANOVA test was used; §, Pearson correlation test was used. In post hoc analysis after ANOVA, a versus b indicates statistically significant differences.Abbreviations: PHQ‐9, Patient Health Questionnaire‐9; SD, Standard deviation.*Significant p‐value at 0.05 level of significance. Depression associated factors among patients with breast cancer. Note: ¥, t‐test; €, one‐way ANOVA test was used; §, Pearson correlation test was used. In post hoc analysis after ANOVA, a versus b indicates statistically significant differences. Abbreviations: PHQ‐9, Patient Health Questionnaire‐9; SD, Standard deviation. Significant p‐value at 0.05 level of significance. Anxiety‐Associated Factors Social status showed a significant association with anxiety (p = 0.002), with widowed patients reporting significantly lower anxiety scores compared to other groups, as indicated by the post hoc analysis. No significant difference in anxiety was found between rural and urban residents (p = 0.130). Age and disease duration were both negatively correlated with anxiety scores, with highly significant p‐values (< 0.001), suggesting that older age and longer disease duration were associated with lower anxiety levels. DM and HTN did not show significant associations with the GAD‐7 scores. Regarding treatments, patients who did not receive chemotherapy or biological therapy had significantly lower anxiety scores compared to those who received these treatments (all p‐values < 0.001). Endocrine therapy, in particular, was associated with notably lower anxiety scores as compared to those who were eligible for chemotherapy (p < 0.001), as shown in Table 3. TABLE 3Anxiety‐associated factors among patients with breast cancer.GAD‐7MeanSDTest‐statistic p Social€Singleb 10.395.5484.980.002* Marriedb 9.825.573Divorcedb 10.935.559Widoweda 7.204.782Residence¥Rural8.695.298−1.540.130Urban9.885.596Diabetes mellitus¥Yes9.785.75−0.4940.622No9.415.41Hypertension¥Yes8.804.891.170.247No9.745.67Age§−0.319< 0.001* Disease duration§−0.409< 0.001* Chemotherapy¥Yes14.812.06−37.3< 0.001* No4.622.218Endocrine therapy¥Yes7.895.24313.96< 0.001* No14.682.311Biological therapy¥Yes14.72.177−16.45< 0.001* No7.24.974 Note: ¥, t‐test; €, one‐way ANOVA test was used; §, Pearson correlation test was used. In post hoc analysis after ANOVA, a versus b indicates statistically significant differences.Abbreviations: GAD‐7, Generalized Anxiety Disorder‐7; SD, Standard deviation.*Significant p‐value at 0.05 level of significance. Anxiety‐associated factors among patients with breast cancer. Note: ¥, t‐test; €, one‐way ANOVA test was used; §, Pearson correlation test was used. In post hoc analysis after ANOVA, a versus b indicates statistically significant differences. Abbreviations: GAD‐7, Generalized Anxiety Disorder‐7; SD, Standard deviation. Significant p‐value at 0.05 level of significance. Quality of Life‐Associated Factors Social status significantly influenced QoL (p < 0.001), with widowed patients reporting the highest mean QoL score (70.21 ± 22.18), while divorced individuals had the lowest (50.29 ± 24.34). Residence did not show a significant association with QoL (p = 0.3). Age (r = 0.298, p < 0.001) and disease duration (r = 0.359, p < 0.001) demonstrated significant positive correlations with QoL, indicating that older age and longer disease duration were linked to better QoL scores. DM and HTN did not show significant associations with QoL scores. Among treatment‐related factors, chemotherapy had a profound impact on QoL (p < 0.001), with patients receiving chemotherapy reporting a significantly lower QoL (33.96 ± 8.28) compared to those who did not (82.16 ± 4.03). Similarly, endocrine therapy was associated with significantly higher QoL (66.09 ± 24.34) than those not receiving it (36.36 ± 7.28, p < 0.001). Additionally, biological therapy had a profound impact on QoL (p < 0.001), with patients receiving biological therapy reporting a significantly lower QoL (34.8 ± 8.3) compared to those who did not (69.8 ± 22.2), as shown in Table 4. TABLE 4Quality of life associated factors among patients with breast cancer.MeanSDTest‐statistic p Social€Singleb 57.5122.476.41< 0.001* Marriedb 57.6825.54Divorcedb 50.2924.34Widoweda 70.2122.18Residence¥Urban57.8125.05−1.040.300Rural61.5324.78Diabetes mellitus¥Yes57.7125.020.5450.586No59.5125.01Hypertension¥Yes58.0325.13−1.030.306No62.1124.32Age§0.298< 0.001* Disease duration§0.359< 0.001* Chemotherapy¥Yes33.968.2857.5< 0.001* No82.164.03Endocrine therapy¥Yes66.0924.3414.74< 0.001* No36.367.28Biological therapy¥Yes34.788.3117.94< 0.001* No69.8022.19 Note: ¥, t‐test; €, one‐way ANOVA test was used; §, Pearson correlation test was used. In post hoc analysis after ANOVA, a versus b indicates statistically significant differences.Abbreviation: SD, Standard deviation.*Significant p‐value at 0.05 level of significance. Quality of life associated factors among patients with breast cancer. Note: ¥, t‐test; €, one‐way ANOVA test was used; §, Pearson correlation test was used. In post hoc analysis after ANOVA, a versus b indicates statistically significant differences. Abbreviation: SD, Standard deviation. Significant p‐value at 0.05 level of significance. Correlation Between Different Assessment Tools A strong positive correlation was found between anxiety and depression, with a coefficient of 0.872 (p < 0.001), indicating that higher anxiety levels were associated with higher depression levels. Both anxiety and depression showed significant negative correlations with QoL, with coefficients of −0.899 and −0.890, respectively (p < 0.001), suggesting that increased anxiety and depression were strongly linked to worse overall QoL. Multivariate Analysis Regarding depression (PHQ‐9 scores) among patients with breast cancer, chemotherapy was a strong and highly significant predictor, with patients undergoing chemotherapy showing higher depression scores (β = 9.550, p < 0.001). The number of chemotherapy cycles was also a significant positive predictor (β = 1.338, p < 0.001), indicating that more cycles were associated with increased depression severity. Additionally, disease duration showed a small but significant negative association with depression (β = −0.050, p = 0.044), suggesting that longer disease duration was linked to lower depression scores. Other factors, including age, residency, DM, HTN, endocrine therapy, and biological therapy, were not significant predictors (all p > 0.05). Overall, chemotherapy, the number of treatment cycles, and disease duration were the key factors influencing depression among these patients (Table 5). TABLE 5Linear regression predictors of depression among patients with breast cancer.PHQ‐9BetaSEt‐statistic p (Constant)6.3561.5134.200< 0.001* Age−0.0040.024−0.1800.857Residency0.3250.4300.7540.451Diabetes Mellitus0.1220.3920.3110.756Hypertension0.3280.4780.6860.494Chemotherapy9.5500.80311.897< 0.001* Endocrine therapy0.4250.6440.6600.510Duration−0.0500.025−2.0280.044* Cycle1.3380.1807.437< 0.001* Biological therapy−0.2970.679−0.4370.663Abbreviations: Beta, regression coefficient; PHQ‐9, Patient Health Questionnaire‐9; SE, standard error.*Significant p‐value at 0.05 level of significance. Linear regression predictors of depression among patients with breast cancer. Abbreviations: Beta, regression coefficient; PHQ‐9, Patient Health Questionnaire‐9; SE, standard error. Significant p‐value at 0.05 level of significance. The linear regression analysis identified predictors of anxiety disorder (GAD‐7 scores) among patients with breast cancer. Chemotherapy was the strongest and most significant predictor, showing a large positive association with anxiety (β = 9.387, p < 0.001). Disease duration was also a significant predictor (β = −0.041, p = 0.022), suggesting that longer disease duration was associated with lower anxiety levels. Other factors, including age, residency, DM, HTN, endocrine therapy, cycle number, and biological therapy, were not statistically significant predictors (p > 0.05). Among these, the number of chemotherapy cycles approached significance (p = 0.056), indicating a potential trend toward higher anxiety with more treatment cycles (Table 6). TABLE 6Linear regression predictors of anxiety disorder among patients with breast cancer.GAD‐7BetaSEt‐statistic p (Constant)6.4121.0975.847< 0.001* Age−0.0260.017−1.5150.131Residency0.3320.3121.0660.287Diabetes Mellitus0.1120.2840.3940.694Hypertension−0.1270.347−0.3650.715Chemotherapy9.3870.58216.137< 0.001* Endocrine therapy0.0120.4660.0260.979Duration−0.0410.018−2.3020.022* Cycle0.2500.1301.9170.056Biological therapy−0.6830.492−1.3880.167Abbreviations: Beta, regression coefficient; GAD‐7, Generalized Anxiety Disorder‐7; SE, standard error.*Significant p‐value at 0.05 level of significance. Linear regression predictors of anxiety disorder among patients with breast cancer. Abbreviations: Beta, regression coefficient; GAD‐7, Generalized Anxiety Disorder‐7; SE, standard error. Significant p‐value at 0.05 level of significance. The linear regression analysis also examined predictors of the total QoL score among patients with breast cancer. Chemotherapy emerged as the strongest and most significant negative predictor, with patients undergoing chemotherapy experiencing markedly lower QoL scores (β = −42.639, p < 0.001). The number of chemotherapy cycles also significantly predicted poorer QoL (β = −2.386, p < 0.001), indicating that more treatment cycles were associated with further reductions in QoL. Endocrine therapy was another significant negative predictor (β = −3.071, p = 0.017), although its impact was less pronounced compared to chemotherapy. Other factors, such as age, residency, DM, HTN, disease duration, and biological therapy, did not significantly predict QoL (all p > 0.05) (Table 7). TABLE 7Linear regression predictors of the total quality of life score among patients with breast cancer.QoLBetaSEt‐statistic p (Constant)85.5343.00028.507< 0.001* Age−0.0030.047−0.0670.947Residency0.6380.8530.7480.455Diabetes Mellitus−0.4000.778−0.5150.607Hypertension0.1300.9490.1370.891Chemotherapy−42.6391.592−26.790< 0.001* Endocrine therapy−3.0711.276−2.4070.017* Duration−0.0300.049−0.6040.546Cycle−2.3860.357−6.688< 0.001* Biological therapy0.4161.3460.3090.758Abbreviations: Beta, regression coefficient; QoL, Quality of life; SE, standard error.*Significant p‐value at 0.05 level of significance. Linear regression predictors of the total quality of life score among patients with breast cancer. Abbreviations: Beta, regression coefficient; QoL, Quality of life; SE, standard error. Significant p‐value at 0.05 level of significance. Discussion This study offers significant insights into the mental health and QoL of individuals afflicted with breast cancer who are receiving adjuvant pharmacotherapy. Significant trends in adjuvant pharmacotherapy indicated probable impacts on psychological well‐being and QoL for patients. The predominant treatments were endocrine, with letrozole and tamoxifen, aligning with the high prevalence of hormone receptor (HR)‐positive disease in the sample, consistent with the literature, whereas treating with the Endocrine therapy showed the highest frequency among treatment options [26]. Despite their potency, many medications have enduring negative effects, such as mood fluctuations, fatigue, and menopausal symptoms, that may exacerbate anxiety or diminish QoL, particularly in postmenopausal women [27, 28]. A substantial proportion of patients received biological therapies, was administered to patients with human epidermal growth factor receptor 2 (HER2)‐positive and triple‐negative conditions, including trastuzumab and pembrolizumab. Treatment with these biological therapies aligns with recently published guidelines [29, 30]. Typically associated with stringent treatment protocols and heightened awareness of adverse effects, these drugs are correlated with psychological stress, particularly during the initial stages of therapy [31]. Notably, over half of the patients did not receive chemotherapy, aligning with the cohort's predominantly early‐stage, HR‐positive profile. The most commonly administered chemotherapy regimens included AC‐T, TCH, and AC‐TH, which are standard combinations used for more aggressive subtypes or node‐positive disease, adhering to the published evidence and guidelines [32]. The median number of cycles was three, indicating that many were still early in their chemotherapy journey, an important period for emotional and physical adjustment. Based on their PHQ‐9 ratings, our cohort of patients with breast cancer exhibited several depressive symptoms. The PHQ‐9 mean score falls within the mild depression range. This aligns with other research from all around the world and in many areas that revealed a lot of depressed cancer patients, particularly those who were still under chemotherapy treatment [33, 34]. Our study found that the prevalence of clinically significant depression was 54.1%, which aligns with findings reported in the literature. A systematic review of 20 studies reported that the prevalence of depressive symptoms among cancer patients (18 studies) ranged from 5.4% to 49.0%, with a pooled prevalence of 21.0%. Fatigue, cognitive impairment, and sexual dysfunction were among the most commonly reported associated symptoms [35]. The GAD‐7 results show that the patients with breast cancer had a moderate level of anxiety, with a prevalence of clinically significant anxiety of 49.6%. This fits with what we already know about cancer patients, where not knowing the diagnosis, treatment, or prognosis can cause long‐lasting worry, especially in the beginning stages of care [36]. Anxiety was reported in a systematic review that included seven studies, with prevalence rates ranging from 3.4% to 43.0% and a pooled prevalence of 21.0%. Similarly, distress was examined in four studies, showing a prevalence range of 4.3% to 11.6%, with a pooled prevalence of 7.0%. These findings are consistent with our results [35]. The EORTC QLQ‐C30 results showed that patients with breast cancer in this study had moderate problems with their general QoL. They scored a median of 5 on a 7‐point scale for global health and QoL, which means they felt fair to good about their well‐being. This fits with other research from the area that found that patients with breast cancer often have a moderate QoL while they are actively being treated, mostly because of physical limitations and mental distress [37, 38]. The study showed that social, demographic, and treatment‐related factors have a big effect on the severity of depression (PHQ‐9 scores) in patients with breast cancer. There was a strong link between social status and depression. Patients who had been widowed had significantly lower depression scores than those who were single, married, or divorced, though this could be because of age differences. This could be a sign of cultural or family support systems that help widows deal with mental stress, whereas divorced patients may lack similar protective social networks [39]. The high scores in single and divorced women also suggest a heightened vulnerability to depressive symptoms among those without stable spousal support during illness. Depressed symptoms were linked to both age and disease duration. This supports the idea that younger patients and those who are just starting treatment are more likely to experience depressed symptoms. International studies have shown that younger women often face bigger emotional and existential problems, especially when breast cancer gets in the way of their plans to build a family, a job, or a relationship [40, 41]. Chemotherapy was strongly associated with severe depressive symptoms compared to those not on chemotherapy. The physical and emotional toll of chemotherapy, including body image changes and functional decline, likely contributes to this marked elevation [42]. Patients not on endocrine therapy reported higher depression scores compared to those on hormonal agents, possibly indicating that endocrine therapy is more often administered in less advanced or hormonally responsive cancers, which may offer patients a sense of treatment optimism [43, 44]. Similarly, those receiving biological therapy had markedly higher depression scores, likely reflecting the more aggressive nature of HER2‐positive disease and its associated psychological burden [45]. Unlike social status, living in a city or a rural area did not have a big effect on depression levels, suggesting that location alone may not be a good way to predict emotional distress. However, differences may still exist in things like access to mental health services and stigma against mental health support [46]. The study also showed that social status has a big effect on the severity of anxiety (GAD‐7 scores) in patients with breast cancer. Patients who had been widowed had much lower anxiety levels than patients who were single, married, or separated, whose mean scores were higher. This result goes against what is thought, since being a widow is often linked to more emotional pain. However, cultural factors in Saudi Arabia, such as stronger familial support for widowed women, may offer buffering effects [47]. This warrants further qualitative exploration. Another explanation is that this relationship might be confounded by age, as most widowed women are older [48]. Age and disease duration were both negatively linked to anxiety. This fits with earlier studies that found younger patients may be more emotionally upset because they worry about their bodies, their ability to have children, and having their lives turned upside down [49]. Similarly, anxiety often peaks near the time of diagnosis and initial treatment, gradually declining with adjustment [50]. Chemotherapy was associated with a dramatically higher anxiety level. This likely reflects both the psychological burden of aggressive therapy and the side effects (e.g., hair loss, nausea, and fatigue) that impact QoL and body image [51, 52]. In contrast, patients on endocrine therapy reported significantly lower anxiety levels than those not on hormonal agents, possibly due to milder side effect profiles compared with other therapeutic agents and their use in more stable disease phases [53]. Similarly, people who received biological therapies had higher worry. This was probably because these were used in more aggressive or HER2‐positive subtypes, where the disease severity or relapse risk is thought to be higher [54, 55]. Moreover, the study showed several important factors that affect the QoL of patients with breast cancer. These include their social position, the type of treatment they receive, and the length of their disease. There was a big effect on QoL scores based on social status. Patients who had been widowed had the best QoL, much better than single, married, and separated patients. This result suggested that widowed patients may get more support from family or be more mentally strong, which is good for their overall health [56]. Conversely, divorced patients appeared to experience a lower QoL, potentially reflecting social isolation or a lack of spousal support during treatment. Age and disease duration were both linked to QoL in a good way. This means that older patients and those who have had their disease longer report a better QoL. This could be because older patients often have less mental discomfort related to issues like body image and fertility, and those who have had cancer for a longer time may have better adapted to living with it, having come up with ways to deal with stress that make them feel stable and healthy [57]. Treatment type had a profound impact on QoL, with chemotherapy patients reporting the lowest QoL compared to those not receiving chemotherapy. The significant QoL decline in chemotherapy patients can be attributed to side effects like fatigue, nausea, and physical debilitation, which heavily impact daily functioning and emotional well‐being [58]. Endocrine therapy was associated with significantly better QoL scores, likely due to the less aggressive side effect profile compared to chemotherapy [27]. Similarly, biological therapy patients had the lowest QoL scores, which may reflect the intensive nature of biological treatments for HER2‐positive cancers and their associated psychological and physical tolls [59]. In the linear regression analysis for predicting depression, chemotherapy was again a key variable, with a strong positive association with depression. This result underscored the psychological toll of chemotherapy, which includes side effects like fatigue, pain, and emotional distress. These factors contribute to higher depression scores in patients undergoing chemotherapy. This aligns with prior studies showing that chemotherapy is associated with increased psychological distress due to its challenging and often debilitating nature [60]. The length of illness has a significant negative association with depression. This means that as the illness lasts longer, depression tends to decrease. This finding showed that patients may eventually get used to their diagnosis and learn new ways to deal with stress, which may lead to fewer depressive symptoms [61]. However, this does not rule out the potential impact of ongoing treatment and its associated psychological burden, which can persist even as patients adjust to the disease. The number of chemotherapy cycles was significantly and positively associated with higher depression scores, implying that the intensity and duration of chemotherapy treatment have a direct and measurable impact on depression. This is consistent with the literature suggesting that repeated cycles of chemotherapy may increase psychosocial stress, particularly when patients face cumulative side effects and prolonged treatment periods [62]. The linear regression analysis for identifying an anxiety disorder revealed that chemotherapy is the most important one because it has a strong positive association with worry. This showed that people who are going through chemotherapy have a lot more anxiety. This was probably because chemotherapy treatments are hard on the body and the mind. Chemotherapy side effects, like tiredness, nausea, and hair loss, and the emotional stress of treatment may make anxiety worse. This showed how important it is for this group of patients to get psychological help and specific interventions [63, 64]. On the other hand, the length of the disease was found to be another important indicator, though it had a negative relationship. This showed that as the disease lasts longer, anxiety levels go down. This could be because many patients go through a process of adapting. Over time, people may find better ways to deal with their symptoms or get used to the fact that they have a long‐term illness, which can make them feel less anxious. This finding fits with earlier studies that showed that having a disease for a longer time can sometimes lead to a sense of control and psychological adjustment [65]. The number of chemotherapy cycles showed a marginally significant effect, suggesting that more chemotherapy cycles may slightly contribute to increased anxiety [8]. However, the effect was not as pronounced as that of chemotherapy as a whole, indicating that other aspects of treatment, such as the type of chemotherapy or psychological support provided during the cycles, may better explain variations in anxiety levels. The linear regression analysis for predicting the total QoL score revealed several important predictors, with chemotherapy showing the most significant negative association. The regression coefficient for chemotherapy indicates that patients undergoing chemotherapy report significantly lower QoL scores. This result is consistent with the known physical and emotional toll that chemotherapy imposes on patients, including fatigue, nausea, pain, and psychological distress. Chemotherapy's significant negative effect on QoL underscores the need for targeted interventions to improve the QoL for patients with breast cancer undergoing such treatments [66]. Endocrine therapy also had a negative impact on QoL, suggesting that even though it may be less physically taxing than chemotherapy, it still significantly affects patients' overall well‐being. This might be due to its associated side effects, such as hot flashes, mood swings, and fatigue, which can significantly impact physical and emotional health [27]. As with anxiety and depression, the number of chemotherapy cycles had a significant negative effect on QoL. This suggests that the cumulative impact of multiple chemotherapy cycles may lead to progressive deterioration in QoL, as patients experience the increasing burden of side effects over time. This finding supports the importance of considering cycle‐based interventions to alleviate the negative impact of treatment on patients' QoL. Study Limitations This study has several limitations. First, its cross‐sectional design precludes causal inference. Second, reliance on self‐reported questionnaires at a single point during ongoing adjuvant therapy rather than at standardized time points relative to treatment cycles introduces the potential for reporting bias. Additionally, the study did not examine the effects of radiotherapy or obesity on the outcomes. No metastasis cases were reported in the study, which may limit external validity. Finally, the relatively small sample size compared to the broader breast cancer population in Saudi Arabia may restrict the generalizability of the findings. Conclusion This study highlights the substantial mental health burden and reduced QoL among Saudi Arabian patients with breast cancer, particularly those receiving adjuvant drug treatments. Over half of the participants reported moderate to severe anxiety and depression (PHQ‐9, GAD‐7), with the highest distress observed in chemotherapy recipients. The EORTC QLQ‐C30 indicated significantly lower QoL in patients on intensive regimens such as chemotherapy or biological therapy. Sociodemographic factors, such as younger age, lower social status, shorter illness duration, and widowhood, were associated with poorer psychological outcomes. These findings underscore the need for targeted psychological support, especially in early treatment stages and for patients undergoing aggressive therapy. Chemotherapy was strongly associated with higher levels of anxiety, depression, and reduced QoL in multivariable analyses. Author Contributions Mahmoud S. Abdallah: conceptualization, funding acquisition, writing – original draft, writing – review and editing, visualization, validation, project administration, supervision, data curation. Ahmed R. Gardouh: conceptualization, writing – review and editing, writing – original draft, project administration, resources, supervision, data curation. Zafaran Khalid Abuaeaaq: investigation, writing – review and editing, writing – original draft, methodology, software, formal analysis, data curation, resources, visualization. Amal Mohammad Badawoud: investigation, writing – original draft, writing – review and editing, project administration, resources, data curation, software, formal analysis, methodology, validation, visualization. Funding The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Acknowledgments The authors would like to thank Princess Nourah bint Abdulrahman University Researchers Supporting Project number (PNURSP2026R418), Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia. Contributor Information Mahmoud S. Abdallah, Email: m.mohamed@jadara.edu.jo. Amal Mohammad Badawoud, Email: ambadawoud@pnu.edu.sa. Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.